Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Y-26763 protects against ischemia/reperfusion injury in dog model

May 26, 1997

Pfizer sponsors large cardiovascular trial in U.K. and Scandinavia

May 26, 1997

Potent, nonpeptide ECE-1/NEP inhibitor discovered by Novartis

May 26, 1997

Mylan receives FDA approval of generic captopril/hydrochlorothiazide

May 23, 1997

Schwarz Pharma and LocalMed work together on antirestenosis drug

May 23, 1997

Disappointing phase III results for Bayer anti-TNF antibody

May 22, 1997

FDA reschedules review date for Heart Laser

May 22, 1997

UR-12670 effective in rat model of endotoxic shock

May 22, 1997

Na+/H+ exchange inhibitors reported by Hoechst

May 22, 1997

Additional GUSTO III data supports efficacy and safety of Retavase

May 21, 1997

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...